Reporting on Adverse Clinical Events, 2019

DOI: 10.1177/0069477019860233

Keywords: Alemtuzumab (160),Angiotensin Receptor Blockers (161),Atorvastatin (166),BEACOPP (163),Benzonatate (162),Cannabinoid,Synthetic (159),Clozapine (172),Dabigatran (173),Dexamethasone (169),Energy Drinks (164),Ipilimumab (167),Methotrexate (168),Methylphenidate (171),Olmesartan (165),Prothrombinex-VF (170),Proton Pump Inhibitors (173)

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text